Shirley R. Kuhlmann Sells 27,500 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Collegium Pharmaceutical Stock Down 0.7 %

Shares of Collegium Pharmaceutical stock opened at $32.96 on Thursday. The company has a 50-day simple moving average of $30.54 and a two-hundred day simple moving average of $34.09. The stock has a market capitalization of $1.06 billion, a PE ratio of 14.21 and a beta of 0.80. Collegium Pharmaceutical, Inc. has a 52-week low of $28.39 and a 52-week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its holdings in shares of Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares in the last quarter. Rubric Capital Management LP increased its holdings in Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares in the last quarter. Victory Capital Management Inc. raised its position in Collegium Pharmaceutical by 43.6% in the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares during the last quarter. Emerald Advisers LLC lifted its stake in Collegium Pharmaceutical by 27.2% during the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after acquiring an additional 177,129 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the last quarter.

Analysts Set New Price Targets

COLL has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.